A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study

Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy

(2011) T. Nakamura et al.   CLINICAL NEPHROLOGY

Hemodynamic Influences of Azelnidipine, a Novel Calcium Channel Blocker, on Cerebral Circulation in Hypertensive Patients with Ischemic White Matter Lesions

(2009) Yasuyuki KIMURA et al.   HYPERTENSION RESEARCH

Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients

(2009) Toshio Ogihara et al.   HYPERTENSION RESEARCH

Prevention of Vascular Injury by Combination of an AT1 Receptor Blocker, Olmesartan, With Various Calcium Antagonists

(2008) Shinji Inaba et al.   AMERICAN JOURNAL OF HYPERTENSION

The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study

(2008) Steven G. Chrysant et al.   CLINICAL THERAPEUTICS

Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes

(2008) Hiroki Ikeda et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Combination Therapy with Renin-Angiotensin System Inhibitors and the Calcium Channel Blocker Azelnidipine Decreases Plasma Inflammatory Markers and Urinary Oxidative Stress Markers in Patients with Diabetic Nephropathy

(2008) Susumu OGAWA et al.   HYPERTENSION RESEARCH

Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients

(2008) Kenneth Jamerson et al.   NEW ENGLAND JOURNAL OF MEDICINE